FIELD: biotechnology; medicine.
SUBSTANCE: invention refers to biotechnology and medicine, namely to oncology, and can be used for suppressing tumour growth in patients suffering colorectal cancer. Disclosed is a method for inhibiting the growth of colorectal cancer tumours in vivo by exposing a genetically modified version of the extracellular domain of TRAIL DR5-B recombinant protein, having an amino acid sequence as presented in SEQ ID NO. 1, on tumour-bearing animals, wherein DR5-B selectively binds to DR5 death receptor and causes death of tumour cells by apoptosis.
EFFECT: tumour growth inhibition reaches 41-46 % and is stably maintained at a relatively high level during 15th to 30th day after the beginning of the exposure.
1 cl, 5 dwg, 3 tbl, 3 ex
| Title | Year | Author | Number | 
|---|---|---|---|
| METHOD OF SUPPRESSING TUMOUR GROWTH | 2012 | 
 | RU2530592C2 | 
| NEW 9-AMINOACRIDONE DERIVATIVE WITH ANTITUMOR AND ANTIMETASTATIC ACTIVITY | 2021 | 
 | RU2810783C2 | 
| METHOD FOR TREATMENT OF SW620 HUMAN COLON CANCER IN EXPERIMENT | 2017 | 
 | RU2665168C1 | 
| RECOMBINANT ALBUMEN WITH ANTI-CANCER EFFECT, GENE CODING IT, AND APPLICATION THEREOF | 2003 | 
 | RU2333221C2 | 
| PHARMACEUTICAL COMPOSITION CONTAINING NANOPARTICLES CONTAINING INSOLUBLE COMPOUND BASED ON CAMPTOTHECIN FOR TREATING CANCER, AND COMBINATION THERAPY USING THEREOF | 2021 | 
 | RU2827894C1 | 
| POLYMER CONTAINING MEDICINAL AGENT BASED ON ANTITUMOR AGENT ETOPOSIDE | 2015 | 
 | RU2595859C1 | 
| METHOD FOR INCREASING EFFECTIVENESS OF IMMUNE CHECKPOINT INHIBITORS USING THERAPEUTIC COMPOSITION BASED ON INDOLE DERIVATIVES AND PROBIOTIC | 2023 | 
 | RU2826495C1 | 
| METHOD FOR TUMOUR CELL DEATH INDUCTION | 2015 | 
 | RU2620165C2 | 
| METHOD OF LUNG CANCER TREATMENT | 2008 | 
 | RU2365370C1 | 
| METHOD OF TREATING MALIGNANCIES IN MAMMALS | 2011 | 
 | RU2461566C1 | 
Authors
Dates
2020-07-17—Published
2019-04-26—Filed